Introduction of biosimilar biologics will not bring about the same price drops as introduction of generic small-molecule drugs, said Rena Conti, an economist at the University of Chicago, whose work focuses on drug pricing.
The stochastic process of stem cell divisions should not be equated with bad luck, said Barnett Kramer, director of the NCI Division of Cancer Prevention, focusing on misinterpretations of the “Bad Luck” paper by Cristian Tomasetti and Bert Vogelstein, of Johns Hopkins University School of Medicine.
As Congress goes into recess and Democrats relinquish their eight-year control of the Senate, advocates for biomedical research are rethinking their approaches to a political reality not observed in nearly a decade: a Republican-controlled Congress.
As an oncologist who treats sarcoma, George Demetri has seen the adverse consequences of power morcellation, the surgical technique widely used to perform laparoscopic hysterectomies and remove putative fibroids.
The Cancer Letter asked Lawrence Einhorn, distinguished professor of medicine and the Livestrong Foundation Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center, to reflect on one of the most spectacular successes in the history of cancer research—his development of the curative regimen for testicular cancer.
The Cancer Letter asked Patrick Loehrer, director of the Indiana University Melvin & Bren Simon Cancer Center, to discuss his institution's decision to close its 10-year-old proton beam center.
The loss of discounts and rebates hospitals received for administering Genentech's Avastin, Herceptin and Rituxan will increase costs to patients, said Scott Soefje, director of pharmacy at University Medical Center Brackenridge in Austin.
A lobbying campaign will make an effort to secure an immediate, significant funding increase for NIH.
Tumor profiling information Caris Life Sciences provides in its reports isn't backed by sufficient evidence to justify some clinical decisions, said Daniel Hayes, a breast cancer expert at the University of Michigan.
Current controversy over power morcellation points to the importance of multidisciplinary education and consultation, said Monica Bertagnolli, chief of the Division of Surgical Oncology at Brigham and Women's Hospital, and professor of surgery at Harvard Medical School.
